Add-on Tiotropium in Chinese Patients With Moderate Asthma: A Pooled Subgroup Analysis of MezzoTinA-Asthma 1 and 2
Open Access
- 1 January 2019
- journal article
- research article
- Published by The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al in Allergy, Asthma & Immunology Research
- Vol. 11 (4) , 519-528
Abstract
Purpose: Asthma affects approximately 30 million patients in China; however, tiotropium data for Chinese patients is limited. This study aimed to assess the efficacy and safety of tiotropium in Chinese patients with moderate symptomatic asthma. Methods: A post hoc subgroup analysis was conducted on 430 Chinese patients pooled from two 24-week, replicate phase 3 trials (NCT01172808 and NCT01172821), in which they received once-daily tiotropium 2.5 mu g (Tio R2.5) or 5 mu g (Tio R5) (n = 106 or 109, respectively), twice-daily salmeterol 50 mu g (Sal 50) (n = 110), or placebo (n = 105), while maintaining inhaled corticosteroids (ICS). The co-primary endpoints assessed in week 24 were forced expiratory volume in 1 second (FEV1) peak(0-3h), response, trough FEV1 response, and responder rate as assessed using the Asthma Control Questionnaire (ACQ). Results: For both FEV1 peak(0-)(3h) responses and trough FEV1 responses, the mean treatment differences were greater for Tio R2.5, no R5, and Sal 50 compared with placebo at 0.249 L, 0.234 L, and 0.284 L, and 0.172 L, 0.180 L, and 0.164 L, respectively (P< 0.001). The ACQ responder rate in placebo, Tio R2.5, Tio R5, and Sal 50 was 58.7%, 62.3%, 59.3%, and 69.1%, respectively. Furthermore, 11 (2.6%) of 430 patients had serious adverse events (Tio R5, n = 4; Tio R2.5, n = 1; Sal 50, n = 1; and placebo, n = 5). Conclusions: Once-daily tiotropium, as add-on to medium-dose ICS, was effective and well tolerated for Chinese patients with moderate symptomatic asthma, consistent with the main analysis.Keywords
Funding Information
- Boehringer Ingelheim
This publication has 13 references indexed in Scilit:
- Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilatorsRespiratory Medicine, 2017
- The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled TrialThe Journal of Allergy and Clinical Immunology: In Practice, 2016
- Magnitude of effect of asthma treatments on Asthma Quality of Life Questionnaire and Asthma Control Questionnaire scores: Systematic review and network meta-analysisJournal of Allergy and Clinical Immunology, 2015
- Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trialsThe Lancet Respiratory Medicine, 2015
- Tiotropium in Asthma Poorly Controlled with Standard Combination TherapyNew England Journal of Medicine, 2012
- Global asthma prevalence in adults: findings from the cross-sectional world health surveyBMC Public Health, 2012
- Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthmaJournal of Allergy and Clinical Immunology, 2011
- Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trialJournal of Allergy and Clinical Immunology, 2011
- Tiotropium Bromide Step-Up Therapy for Adults with Uncontrolled AsthmaNew England Journal of Medicine, 2010
- Systemic side effects of inhaled corticosteroids in patients with asthmaRespiratory Medicine, 2006